Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Serum Levels of Anti-PON1 and Anti-HDL Antibodies as Potential Biomarkers of Premature Atherosclerosis in Systemic Lupus Erythematosus.

Thrombosis and haemostasis - 1 Nov 2017

López Patricia, Rodríguez-Carrio Javier, Martínez-Zapico Aleida, Pérez-Álvarez Ángel I, López-Mejías Raquel, Benavente Lorena, Mozo Lourdes, Caminal-Montero Luis, González-Gay Miguel A, Suárez Ana

Abstract excerpt

The present study aimed to evaluate the possible role of immunoglobulin G (IgG) antibodies against high-density lipoproteins (HDL) and paraoxonase 1 (PON1) as possible biomarkers of cardiovascular disease (CVD) in systemic lupus erythematosus (SLE). To this end, levels of these autoantibodies, PON1 activity and total antioxidant capacity were quantified in serum samples from 198 SLE patients, 100 healthy controls...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antioxidants
Share to Aryldialkylphosphatase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carotid Artery Diseases

Share to Carotid Intima-Media Thickness

Share to Immunoglobulin G

Share to Lipoproteins, HDL

Share to Lupus Erythematosus, Systemic

Share to Ultrasonography, Doppler

Source

Identifiers

PMID: 29044294
DOI: 10.1160/TH17-03-0221

Genes

PON1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serum Levels of Anti-PON1 and Anti-HDL Antibodies as Potential Biomarkers of Premature Atherosclerosis in Systemic Lupus Erythematosus.PMID 29044294Read ↗

Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus.Semantic proximity Read ↗

Systemic lupus erythematosus-accelerated atherosclerosis: mechanistic insights and clinical implications.Semantic proximity Read ↗

Paraoxonase 1 Activity Is Modulated by the rs662 Polymorphism and IgG Anti-High-Density Lipoprotein Antibodies in Patients With Rheumatoid Arthritis: Potential Implications for Cardiovascular Disease.Semantic proximity Read ↗

Cardiovascular Risk in Systemic Lupus Erythematosus: A Cross-Sectional Analysis of NHANES 2001–2023Semantic proximity Read ↗

Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus.Semantic proximity Read ↗

Autoantibodies against complement component C1q in systemic lupus erythematosusSemantic proximity Read ↗

HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular DiseasesSemantic proximity Read ↗

Role of microRNAs in the Development of Cardiovascular Disease in Systemic Autoimmune DisordersSemantic proximity Read ↗

Synergism between apolipoprotein E Ɛ4 allele and paraoxonase (PON1) 55-M allele is associated with risk of systemic lupus erythematosus.Semantic proximity Read ↗

Paraoxonase (PON1) 55 polymorphism and association with systemic lupus erythematosus.Semantic proximity Read ↗

Cardiovascular Consequences of Autoimmune Rheumatic Diseases.Semantic proximity Read ↗

The Molecular Bases of Anti-oxidative and Anti-inflammatory Properties of Paraoxonase 1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.